Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Immunology | US/EU | 2021

Login to access report north_east
Contact sales account_box

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity for biosimilar developers. The pipeline of immune biosimilars includes several agents that reference AbbVie’s very successful biologic Humira (adalimumab). Biosimilars of Humira have been available in Europe since October 2018. Biosimilars referencing Roche’s Rituxan / MabThera (rituximab) have also launched in Europe and the United States. As the immune biosimilar space becomes increasingly competitive, it is important that manufacturers and marketers of biosimilars and branded biologics understand the factors that most influence physicians’ choice of therapy. Clarivate conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights into their attitude toward biosimilars, the drivers of and barriers to their use of biosimilars, and their expectations for future biosimilar adoption.

Questions answered:

  • Have physicians received recommendations to use biosimilars?
  • Are physicians switching patients from reference brands to biosimilars?
  • What factors do physicians consider when choosing between competing biosimilars?
  • How are TNF-alpha inhibitor and MAb biosimilars performing, and what are physicians’ expectations for their future uptake?
  • What are the key drivers of and barriers to the uptake of TNF-alpha inhibitor and MAb biosimilars?

Scope:

  • Markets covered: France, Germany, and the United States.
  • Primary research: Survey of 90 rheumatologists and 92 gastroenterologists.

Key companies mentioned:

  • Amgen
  • AbbVie
  • Biogen
  • Celltrion
  • Johnson & Johnson / Janssen
  • Merck & Co. / MSD
  • Mundipharma
  • Novartis / Sandoz
  • Pfizer / Hospira
  • Roche / Genentech
  • Samsung Bioepis

Key drugs mentioned:

  • Inflectra (infliximab)
  • Remsima (infliximab)
  • Benepali (etanercept)
  • Flixabi (infliximab)
  • Truxima (rituximab)
  • Enbrel (etanercept)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Rituxan / MabThera (rituximab)
  • Simponi (golimumab)
  • Cimzia (certolizumab pegol)
  • Orencia (abatacept)
  • Actemra / RoActemra (tocilizumab)
  • Stelara (ustekinumab)
  • Entyvio (vedolizumab)
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east